▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #730 by analyst upside · 2026-09-26
DYN
Dyne Therapeutics, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+132.1%
implied upside to consensus target
Current Price $16.03
Consensus Target $37.2
Bull Target $50.0
Bear Target $10.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
11
Hold
0
Sell
1
52-Week Low $11.92
52-Week High $27.3
YTD Return -13.4%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.26
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.92
52-Week High $27.3
Current Price $16.03
Bear Target $10.0
Bull Target $50.0
● Now $16.03 ● Target $37.2
TRADING DATA
Avg Volume 2.7M
YTD Return -13.4%
Analyst Count 15
Consensus Buy
Upside to Target +132.1%
Last Updated 2026-09-26

ANALYST SUMMARY

Dyne Therapeutics, Inc. (DYN) is currently trading at $16.03 with a Wall Street consensus price target of $37.2, implying potential upside of 132.1% over the next 12 months. 15 analysts currently cover DYN, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $10.0.

DYN operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 13.4% year-to-date and is currently trading near the lower end of its 52-week range of $11.92 – $27.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
ACAD +56.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 9.3x · Buy
GTBIF +106.5%
Green Thumb Industries Inc.
$2B · P/E 14.4x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy
INDV +36.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DYN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-09 Building track record
JP Morgan ↓ Downgrade
Neutral → Underweight 2026-09-09 43% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-09-09 Building track record
Baird - Reiterated
Outperform → Outperform 2026-09-09 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-31 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-30 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-07-23 40% win rate (10 calls)
TD Cowen ● Initiated
Buy 2026-06-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →